

**TOXICOLOGICAL PROFILE FOR
HEXACHLOROBENZENE**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

September 2002

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.


Julie Louise Gerberding, M.D., M.P.H.
Administrator
Agency for Toxic Substances and
Disease Registry

*Legislative Background

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepared toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see *Federal Register* notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by *type of health effect* (death, systemic, immunologic, reproductive), by *route of exposure*, and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

- Section 1.6** **How Can (Chemical X) Affect Children?**
- Section 1.7** **How Can Families Reduce the Risk of Exposure to (Chemical X)?**
- Section 3.7** **Children's Susceptibility**
- Section 6.6** **Exposures of Children**

Other Sections of Interest:

- Section 3.8** **Biomarkers of Exposure and Effect**
 - Section 3.11** **Methods for Reducing Toxic Effects**
-

ATSDR Information Center

Phone: 1-888-42-ATSDR or (404) 498-0110 **Fax:** (404) 498-0057
E-mail: atsdric@cdc.gov **Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Jessilynn Taylor, M.S.
ATSDR, Division of Toxicology, Atlanta, Georgia

Jewell Wilson, Ph.D.
ATSDR, Division of Toxicology, Atlanta, Georgia

Marc Odin, M.S., D.A.B.T.
Syracuse Research Corporation, North Syracuse, New York

Andrew J. McDougal, Ph.D.
Syracuse Research Corporation, North Syracuse, New York

Richard J. Amata, Ph.D.
Syracuse Research Corporation, North Syracuse, New York

Philip Howard, Ph.D.
Syracuse Research Corporation, North Syracuse, New York

Farzana Dalal, B.S.
Syracuse Research Corporation, North Syracuse, New York

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

PEER REVIEW

A peer review panel was assembled for hexachlorobenzene. The panel consisted of the following members:

1. Dr. Syed M. GhiasUddin, Indiana Department of Environmental Management, 1815 Beckenbauer Lane, Indianapolis, IN 46214;
2. Dr. Kannan Krishnan, University of Montreal, Faculty of Medicine, 2375 Chemin de la Cote Ste-Catherine, Room 4105, Montreal, QC H3T 1A8; and
3. Dr. Clint Skinner, Skinner Associates, Consultants in Toxicology, 3985 Shooting Star Road, Creston, CA 93432.

These experts collectively have knowledge of hexachlorobenzene's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS HEXACHLOROBENZENE?	1
1.2 WHAT HAPPENS TO HEXACHLOROBENZENE WHEN IT ENTERS THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO HEXACHLOROBENZENE?	2
1.4 HOW CAN HEXACHLOROBENZENE ENTER AND LEAVE MY BODY?	3
1.5 HOW CAN HEXACHLOROBENZENE AFFECT MY HEALTH?	4
1.6 HOW CAN HEXACHLOROBENZENE AFFECT CHILDREN?	5
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO HEXACHLOROBENZENE?	7
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO HEXACHLOROBENZENE?	8
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	9
1.10 WHERE CAN I GET MORE INFORMATION?	10
2. RELEVANCE TO PUBLIC HEALTH	11
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO HEXACHLOROBENZENE IN THE UNITED STATES	11
2.2 SUMMARY OF HEALTH EFFECTS	12
2.3 MINIMAL RISK LEVELS (MRLs)	16
3. HEALTH EFFECTS	23
3.1 INTRODUCTION	23
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	23
3.2.1 Inhalation Exposure	25
3.2.1.1 Death	25
3.2.1.2 Systemic Effects	25
3.2.1.3 Immunological and Lymphoreticular Effects	33
3.2.1.4 Neurological Effects	34
3.2.1.5 Reproductive Effects	34
3.2.1.6 Developmental Effects	35
3.2.1.7 Cancer	35
3.2.2 Oral Exposure	36

3.2.2.1	Death	36
3.2.2.2	Systemic Effects	38
3.2.2.3	Immunological and Lymphoreticular Effects	95
3.2.2.4	Neurological Effects	99
3.2.2.5	Reproductive Effects	102
3.2.2.6	Developmental Effects	107
3.2.2.7	Cancer	111
3.2.3	Dermal Exposure	115
3.2.3.1	Death	115
3.2.3.2	Systemic Effects	115
3.2.3.3	Immunological and Lymphoreticular Effects	115
3.2.3.4	Neurological Effects	115
3.2.3.5	Reproductive Effects	115
3.2.3.6	Developmental Effects	115
3.2.3.7	Cancer	116
3.3	GENOTOXICITY	116
3.4	TOXICOKINETICS	118
3.4.1	Absorption	123
3.4.1.1	Inhalation Exposure	123
3.4.1.2	Oral Exposure	125
3.4.1.3	Dermal Exposure	128
3.4.2	Distribution	129
3.4.2.1	Inhalation Exposure	129
3.4.2.2	Oral Exposure	130
3.4.2.3	Dermal Exposure	135
3.4.3	Metabolism	135
3.4.3.1	Inhalation Exposure	135
3.4.3.2	Oral Exposure	135
3.4.3.3	Dermal Exposure	140
3.4.4	Elimination and Excretion	140
3.4.4.1	Inhalation Exposure	140
3.4.4.2	Oral Exposure	141
3.4.4.3	Dermal Exposure	143
3.4.4.4	Other Routes of Exposure	143
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	143
3.4.5.1	Summary of PBPK Models	145
3.4.5.2	Hexachlorobenzene PBPK Model Comparison	145
3.4.5.3	Discussion of Models	147
3.5	MECHANISMS OF ACTION	149
3.5.1	Pharmacokinetic Mechanisms	149
3.5.2	Mechanisms of Toxicity	152
3.5.3	Animal-to-Human Extrapolations	155
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	155
3.7	CHILDREN'S SUSCEPTIBILITY	157
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	160
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Hexachlorobenzene	161
3.8.2	Biomarkers Used to Characterize Effects Caused by Hexachlorobenzene	162
3.9	INTERACTIONS WITH OTHER CHEMICALS	163
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	167
3.11	METHODS FOR REDUCING TOXIC EFFECTS	168

3.11.1	Reducing Peak Absorption Following Exposure	168
3.11.2	Reducing Body Burden	169
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	170
3.12	ADEQUACY OF THE DATABASE	171
3.12.1	Existing Information on Health Effects of Hexachlorobenzene	172
3.12.2	Identification of Data Needs	172
3.12.3	Ongoing Studies	186
4.	CHEMICAL AND PHYSICAL INFORMATION	187
4.1	CHEMICAL IDENTITY	187
4.2	PHYSICAL AND CHEMICAL PROPERTIES	187
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	191
5.1	PRODUCTION	191
5.2	IMPORT/EXPORT	192
5.3	USE	194
5.4	DISPOSAL	194
6.	POTENTIAL FOR HUMAN EXPOSURE	197
6.1	OVERVIEW	197
6.2	RELEASES TO THE ENVIRONMENT	200
6.2.1	Air	201
6.2.2	Water	204
6.2.3	Soil	206
6.3	ENVIRONMENTAL FATE	208
6.3.1	Transport and Partitioning	208
6.3.2	Transformation and Degradation	213
6.3.2.1	Air	213
6.3.2.2	Water	214
6.3.2.3	Sediment and Soil	215
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	216
6.4.1	Air	217
6.4.2	Water	219
6.4.3	Sediment and Soil	220
6.4.4	Other Environmental Media	222
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	232
6.6	EXPOSURES OF CHILDREN	236
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	240
6.8	ADEQUACY OF THE DATABASE	242
6.8.1	Identification of Data Needs	243
6.8.2	Ongoing Studies	248
7.	ANALYTICAL METHODS	250
7.1	BIOLOGICAL MATERIALS	250
7.2	ENVIRONMENTAL SAMPLES	254
7.3	ADEQUACY OF THE DATABASE	261
7.3.1	Identification of Data Needs	262
7.3.2	Ongoing Studies	264
8.	REGULATIONS AND ADVISORIES	266

9. REFERENCES 274

10. GLOSSARY 346

APPENDICES

A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS A-1

B. USER'S GUIDE B-1

C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS C-1

D. INDEX D-1

LIST OF FIGURES

3-1. Levels of Significant Exposure to Hexachlorobenzene - Inhalation	30
3-2. Levels of Significant Exposure to Hexachlorobenzene - Oral	70
3-3. Metabolism and Urinary Metabolites of Hexachlorobenzene	139
3-4. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	146
3-5. Existing Information on Health Effects of Hexachlorobenzene	174
6-1. Frequency of NPL Sites with Hexachlorobenzene Contamination	198

LIST OF TABLES

3-1. Levels of Significant Exposure to Hexachlorobenzene - Inhalation	27
3-2. Levels of Significant Exposure to Hexachlorobenzene - Oral	39
3-3. Genotoxicity of Hexachlorobenzene <i>In Vivo</i>	119
3-4. Genotoxicity of Hexachlorobenzene <i>In Vitro</i>	120
4-1. Chemical Identity of Hexachlorobenzene	188
4-2. Physical and Chemical Properties of Hexachlorobenzene	189
5-1. Facilities that Produce, Process, or Use Hexachlorobenzene	193
6-1. U.S. Hexachlorobenzene Emissions Summary, Mid 1990s, Part A	202
6-1. U.S. Hexachlorobenzene Emissions Summary, Mid 1990s, Part B	203
6-2. Releases to the Environment From Facilities That Produce, Process, or Use Hexachlorobenzene	205
6-3. Sites with the Five Highest Concentrations of Hexachlorobenzene in Fish	225
6-4. Residue Concentrations (ng/g) in Snapping Turtle Eggs from Five Locations Collected in 1981–1991	228
6-5. Mean Levels of Hexachlorobenzene in Breast Milk	238
6-6. Fish Consumption Advisories	241
7-1. Analytical Methods for Determining Hexachlorobenzene in Biological Samples	251
7-2. Analytical Methods for Determining Hexachlorobenzene in Environmental Samples	255
7-3. Analytical Methods for Determining Biomarkers of Hexachlorobenzene	263
8-1. Regulations and Guidelines Applicable to Hexachlorobenzene	268

